Waning intra-season vaccine effectiveness against influenza A(H3N2) underlines the need for more durable protection

References

• World Health Organization (WHO). Vaccines against influenza: WHO position paper – May 2022. Wkly Epidemiol Rec. 2022;97(19):185–208.
   Google Scholar
• Sellers SA, Hagan RS, Hayden FG, et al. The hidden burden of influenza: a review of the extra-pulmonary complications of influenza infection. Influenza Other Respir Viruses. 2017;11(5):372–393. doi: 10.1111/irv.12470
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Past seasons’ vaccine effectiveness estimates. [cited 2023 Nov 15]. Available from: https://www.cdc.gov/flu/vaccines-work/past-seasons-estimates.html
   Google Scholar
• Domnich A, Manini I, Calabrò GE, et al. Mapping host-related correlates of influenza vaccine-induced immune response: an umbrella review of the available systematic reviews and meta-analyses. Vaccines (Basel). 2019;7(4):215. doi: 10.3390/vaccines7040215
   PubMed Web of Science ®Google Scholar
• Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016;16(8):942–951. doi: 10.1016/s1473-3099(16)00129-8
   PubMed Web of Science ®Google Scholar
• Domnich A, Manini I, Panatto D, et al. Immunogenicity measures of influenza vaccines: a study of 1164 registered clinical trials. Vaccines (Basel). 2020;8(2):325. doi: 10.3390/vaccines8020325
   PubMed Web of Science ®Google Scholar
• Wen S, Wu Z, Zhong S, et al. Factors influencing the immunogenicity of influenza vaccines. Hum Vaccin Immunother. 2021;17(8):2706–2718. doi: 10.1080/21645515.2021.1875761
   PubMed Web of Science ®Google Scholar
• Rastogi S, Gross PA, Bonelli J, et al. Time to peak serum antibody response to influenza vaccine. Clin Diagn Lab Immunol. 1995;2(1):120–121. doi: 10.1128/cdli.2.1.120-121.1995
   PubMedGoogle Scholar
• Kositanont U, Assantachai P, Wasi C, et al. Kinetics of the antibody response to seasonal influenza vaccination among the elderly. Viral Immunol. 2012;25(6):471–476. doi: 10.1089/vim.2012.0024
   PubMed Web of Science ®Google Scholar
• Doyon-Plourde P, Przepiorkowski J, Young K, et al. Intraseasonal waning immunity of seasonal influenza vaccine – a systematic review and meta-analysis. Vaccine. 2023;41(31):4462–4471.
   PubMed Web of Science ®Google Scholar
• Hoa LNM, Sullivan SG, Mai LQ, et al. Influenza A(H1N1)pdm09 but not A(H3N2) virus infection induces durable seroprotection: results from the ha nam cohort. J Infect Dis. 2022;226(1):59–69. doi: 10.1093/infdis/jiaa293
   PubMed Web of Science ®Google Scholar
• Carlock MA, Ingram JG, Clutter EF, et al. Impact of age and pre-existing immunity on the induction of human antibody responses against influenza B viruses. Hum Vaccin Immunother. 2019;15(9):2030–2043. doi: 10.1080/21645515.2019.1642056
   PubMed Web of Science ®Google Scholar
• Gilbert PB, Fong Y, Juraska M, et al. HAI and NAI titer correlates of inactivated and live attenuated influenza vaccine efficacy. BMC Infect Dis. 2019;19(1):453. doi: 10.1186/s12879-019-4049-5
   PubMedGoogle Scholar
• Ferdinands JM, Fry AM, Reynolds S, et al. Intraseason waning of influenza vaccine protection: evidence from the US influenza vaccine effectiveness network, 2011–12 through 2014–15. Clin Infect Dis. 2017;64(5):544–550.
   PubMed Web of Science ®Google Scholar
• Ferdinands JM, Gaglani M, Martin ET, et al. Waning vaccine effectiveness against influenza-associated hospitalizations among adults, 2015–2016 to 2018–2019, United States Hospitalized Adult Influenza Vaccine Effectiveness Network. Clin Infect Dis. 2021;73(4):726–729.
   PubMed Web of Science ®Google Scholar
• Hu W, Sjoberg PA, Fries AC, et al. Waning vaccine protection against influenza among department of defense adult beneficiaries in the United States, 2016–2017 through 2019–2020 influenza seasons. Vaccines (Basel). 2022;10(6):888.
   PubMed Web of Science ®Google Scholar
• Young B, Sadarangani S, Jiang L, et al. Duration of influenza vaccine effectiveness: a systematic review, meta-analysis, and meta-regression of test-negative design case-control studies. J Infect Dis. 2018;217(5):731–741. doi: 10.1093/infdis/jix632
   PubMed Web of Science ®Google Scholar
• Radin JM, Hawksworth AW, Myers CA, et al. Influenza vaccine effectiveness: maintained protection throughout the duration of influenza seasons 2010-2011 through 2013–2014. Vaccine. 2016;34(33):3907–3912.
   PubMed Web of Science ®Google Scholar
• Petrie JG, Ohmit SE, Truscon R, et al. Modest waning of influenza vaccine efficacy and antibody titers during the 2007–2008 influenza season. J Infect Dis. 2016;214(8):1142–1149.
   PubMed Web of Science ®Google Scholar
• Kissling E, Nunes B, Robertson C, et al. I-MOVE multicentre case-control study 2010/11 to 2014/15: is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination? Euro Surveill. 2016;21(16). doi: 10.2807/1560-7917.es.2016.21.16.30201
   Google Scholar
• Lipsitch M, Goldstein E, Ray GT, et al. Depletion-of-susceptibles bias in influenza vaccine waning studies: how to ensure robust results. Epidemiol Infect. 2019;147:e306. doi: 10.1017/S0950268819001961
   PubMedGoogle Scholar
• Ray GT, Lewis N, Klein NP, et al. Intraseason waning of influenza vaccine effectiveness. Clin Infect Dis. 2019;68(10):1623–1630. doi: 10.1093/cid/ciy770
   PubMed Web of Science ®Google Scholar
• Chung H, Campitelli MA, Buchan SA, et al. Measuring waning protection from seasonal influenza vaccination during nine influenza seasons, Ontario, Canada, 2010/11 to 2018/19. Euro Surveill. 2024;29(8). doi: 10.2807/1560-7917.ES.2024.29.8.2300239.
   PubMedGoogle Scholar
• Costantino V, Trent M, MacIntyre CR. Modelling of optimal timing for influenza vaccination as a function of intraseasonal waning of immunity and vaccine coverage. Vaccine. 2019;37(44):6768–6775. doi: 10.1016/j.vaccine.2019.08.069.
   PubMed Web of Science ®Google Scholar
• Newall AT, Chen C, Wood JG, et al. Within-season influenza vaccine waning suggests potential net benefits to delayed vaccination in older adults in the United States. Vaccine. 2018;36(39):5910–5915. doi: 10.1016/j.vaccine.2018.08.007.
   PubMed Web of Science ®Google Scholar
• DRIVE consortium. Core protocol for type/brand specific influenza vaccine effectiveness studies (test-negative design studies). [cited 2023 Nov 15]. Available from: https://www.drive-eu.org/index.php/results/deliverables/
   Google Scholar
• Domnich A, Orsi A, Ogliastro M, et al. Influenza vaccine effectiveness in preventing hospital encounters for laboratory-confirmed infection among Italian adults, 2022/23 season. Vaccine. 2023;41(33):4861–4866. doi: 10.1016/j.vaccine.2023.06.072
   PubMed Web of Science ®Google Scholar
• Rizzo C, Gesualdo F, Loconsole D, et al. Moderate vaccine effectiveness against severe acute respiratory infection caused by A(H1N1)pdm09 influenza virus and no effectiveness against A(H3N2) influenza virus in the 2018/2019 season in Italy. Vaccines (Basel). 2020;8(3):427.
   PubMed Web of Science ®Google Scholar
• Panatto D, Domnich A, Chironna M, et al. Surveillance of severe acute respiratory infection and influenza vaccine effectiveness among hospitalized Italian adults, 2021/22 season. Vaccines (Basel). 2022;11(1):83. doi: 10.3390/vaccines11010083
   PubMed Web of Science ®Google Scholar
• Tenforde MW, Chung J, Smith ER, et al. Influenza vaccine effectiveness in inpatient and outpatient settings in the United States, 2015–2018. Clin Infect Dis. 2021;73(3):386–392.
   PubMed Web of Science ®Google Scholar
• Doll MK, Pettigrew SM, Ma J, et al. Effects of confounding bias in coronavirus disease 2019 (COVID-19) and influenza vaccine effectiveness test-negative designs due to correlated influenza and COVID-19 vaccination behaviors. Clin Infect Dis. 2022;75(1):e564–e571. doi: 10.1093/cid/ciac234
   PubMed Web of Science ®Google Scholar
• Puig-Barberà J, Mira-Iglesias A, Tortajada-Girbés M, et al. Waning protection of influenza vaccination during four influenza seasons, 2011/2012 to 2014/2015. Vaccine. 2017;35(43):5799–5807. doi: 10.1016/j.vaccine.2017.09.035
   PubMed Web of Science ®Google Scholar
• Belongia EA, Sundaram ME, McClure DL, et al. Waning vaccine protection against influenza a (H3N2) illness in children and older adults during a single season. Vaccine. 2015;33(1):246–251. doi: 10.1016/j.vaccine.2014.06.052
   PubMed Web of Science ®Google Scholar
• Belongia EA, McLean HQ. Influenza vaccine effectiveness: Defining the H3N2 problem. Clin Infect Dis. 2019;69(10):1817–1823. doi: 10.1093/cid/ciz411
   PubMed Web of Science ®Google Scholar
• Pando R, Stern S, Nemet I, et al. Diversity in the circulation of influenza A(H3N2) viruses in the Northern Hemisphere in the 2018-19 season. Vaccines (Basel). 2021;9(4):375.
   PubMed Web of Science ®Google Scholar
• Song JY, Cheong HJ, Hwang IS, et al. Long-term immunogenicity of influenza vaccine among the elderly: risk factors for poor immune response and persistence. Vaccine. 2010;28(23):3929–3935. doi: 10.1016/j.vaccine.2010.03.067
   PubMed Web of Science ®Google Scholar
• Cobey S, Gouma S, Parkhouse K, et al. Poor immunogenicity, not vaccine strain egg adaptation, may explain the low H3N2 influenza vaccine effectiveness in 2012–2013. Clin Infect Dis. 2018;67(3):327–333.
   PubMed Web of Science ®Google Scholar
• Jones-Gray E, Robinson EJ, Kucharski AJ, et al. Does repeated influenza vaccination attenuate effectiveness? A systematic review and meta-analysis. Lancet Respir Med. 2023;11(1):27–44. doi: 10.1016/S2213-2600(22)00266-1
   PubMed Web of Science ®Google Scholar
• Thompson MG, Naleway A, Fry AM, et al. Effects of repeated annual inactivated influenza vaccination among healthcare personnel on serum hemagglutinin inhibition antibody response to A/Perth/16/2009 (H3N2)-like virus during 2010–11. Vaccine. 2016;34(7):981–988. doi: 10.1016/j.vaccine.2015.10.119
   PubMed Web of Science ®Google Scholar
• Thompson MG, Cowling BJ. How repeated influenza vaccination effects might apply to COVID-19 vaccines. Lancet Respir Med. 2022;10(7):636–638. doi: 10.1016/S2213-2600(22)00162-X
   PubMed Web of Science ®Google Scholar
• Debbink K, McCrone JT, Petrie JG, et al. Vaccination has minimal impact on the intrahost diversity of H3N2 influenza viruses. PLoS Pathog. 2017;13(1):e1006194. doi: 10.1371/journal.ppat.1006194
   PubMed Web of Science ®Google Scholar
• Seidman JC, Richard SA, Viboud C, et al. Quantitative review of antibody response to inactivated seasonal influenza vaccines. Influenza Other Respir Viruses. 2012;6(1):52–62. doi: 10.1111/j.1750-2659.2011.00268.x
   PubMed Web of Science ®Google Scholar
• Sumner KM, Masalovich S, O’Halloran A, et al. Severity of influenza-associated hospitalisations by influenza virus type and subtype in the USA, 2010–19: a repeated cross-sectional study. Lancet Microbe. 2023;4(11):e903–e912.
   PubMedGoogle Scholar
• Stuurman AL, Levi M, Beutels P, et al. Investigating confounding in network-based test-negative design influenza vaccine effectiveness studies-experience from the DRIVE project. Influenza Other Respir Viruses. 2023;17(1):e13087.
   PubMed Web of Science ®Google Scholar
• European Centres for Disease Prevention and Control (ECDC). Summary of the influenza 2016–2017 season in Europe. [cited 2023 Nov 15]. Available from: https://www.ecdc.europa.eu/en/publications-data/summary-influenza-2016-2017-season-europe#:~:text=The%20season%20lasted%20for%2027,%2F2016%20and%205%2F2017
   Google Scholar
• European Centres for Disease Prevention and Control (ECDC). Seasonal influenza 2022−2023. Annual epidemiological report for 2023 [cited 2023 Nov 15]. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/seasonal-influenza-annual-epidemiological-report-2022-2023.pdf
   Google Scholar
• Domnich A, Orsi A, Ogliastro M, et al. Exploring missed opportunities for influenza vaccination and influenza vaccine co-administration patterns among Italian older adults: a retrospective cohort study. Eur J Public Health. 2023;33(6):1183–1187. doi: 10.1093/eurpub/ckad155
   PubMed Web of Science ®Google Scholar
• Italian Ministry of Health. Prevention and control of influenza: recommendations for the 2023-24 season. [cited 2023 Nov 15]. Available from: https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2023&codLeg=93294&parte=1%20&serie=null
   Google Scholar
• Williams KV, Krauland MG, Harrison LH, et al. Can a two-dose influenza vaccine regimen better protect older adults? An agent-based modeling study. Vaccines (Basel). 2022;10(11):1799. doi: 10.3390/vaccines10111799
   PubMed Web of Science ®Google Scholar
• Cordero E, Roca-Oporto C, Bulnes-Ramos A, et al. Two doses of inactivated influenza vaccine improve immune response in solid organ transplant recipients: Results of TRANSGRIPE 1–2, a randomized controlled clinical trial. Clin Infect Dis. 2017;64(7):829–838.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Nahi H, Linde A. Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. Br J Haematol. 2005;130(1):96–98. doi: 10.1111/j.1365-2141.2005.05582.x
   PubMed Web of Science ®Google Scholar
• Nunes MC, Cutland CL, Moultrie A, et al. Immunogenicity and safety of different dosing schedules of trivalent inactivated influenza vaccine in pregnant women with HIV: a randomised controlled trial. Lancet HIV. 2020;7(2):e91–e103. doi: 10.1016/S2352-3018(19)30322-4
   PubMed Web of Science ®Google Scholar
• Domnich A, de Waure C. Comparative effectiveness of adjuvanted versus high-dose seasonal influenza vaccines for older adults: a systematic review and meta-analysis. Int J Infect Dis. 2022;122:855–863. doi: 10.1016/j.ijid.2022.07.048
   PubMed Web of Science ®Google Scholar
• Grohskopf LA, Blanton LH, Ferdinands JM, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2023–24 influenza season. MMWR Recomm Rep. 2023;72(2):1–25. doi: 10.15585/mmwr.rr7202a1
   Web of Science ®Google Scholar
• Noh JY, Song JY, Choi WS, et al. Immunogenicity of trivalent influenza vaccines in patients with chronic kidney disease undergoing hemodialysis: MF59-adjuvanted versus non-adjuvanted vaccines. Hum Vaccin Immunother. 2016;12(11):2902–2908. doi: 10.1080/21645515.2016.1191717
   PubMed Web of Science ®Google Scholar
• Shartouny JR, Lowen AC. Message in a bottle: mRNA vaccination for influenza. J Gen Virol. 2022;103(7):001765. doi: 10.1099/jgv.0.001765
   PubMed Web of Science ®Google Scholar
• Shinde V, Cho I, Plested JS, et al. Comparison of the safety and immunogenicity of a novel matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial. Lancet Infect Dis. 2022;22(1):73–84. doi: 10.1016/s1473-3099(21)00192-4
   PubMed Web of Science ®Google Scholar